Sancuso Side Effects
Generic name: granisetron
Note: This document contains side effect information about granisetron. Some of the dosage forms listed on this page may not apply to the brand name Sancuso.
Some side effects of Sancuso may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
For the Consumer
Applies to granisetron: oral solution, oral tablet
Other dosage forms:
Get emergency medical help if you have any of these signs of an allergic reaction while taking granisetron (the active ingredient contained in Sancuso) hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have a serious side effect such as:
fast or pounding heartbeats;
fever, body aches, flu symptoms; or
easy bruising or bleeding; unusual weakness.
Less serious side effects of granisetron may include:
stomach pain or upset, loss of appetite;
diarrhea or constipation;
sleep problems (insomnia);
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.
For Healthcare Professionals
Applies to granisetron: intravenous solution, oral solution, oral tablet, transdermal film extended release
Nervous system side effects have been reported the most frequently. These have included headache (up to 15% to 52.2%), dizziness (5% to 26.1%), insomnia (5%), anxiety (2%), somnolence (1%), asthenia, agitation, and stimulation. Headache (0.7%) has been reported in patients using the granisetron (the active ingredient contained in Sancuso) transdermal system. One case compatible with, but not diagnostic of, extrapyramidal symptoms has been reported.
Granisetron-induced headache is generally mild. In clinical trials, headache typically resolved spontaneously or was relieved by analgesics.
Gastrointestinal side effects have included nausea (20%), constipation (3% to 50%), vomiting (12%), diarrhea (4% to 9%), abdominal pain (4% to 6%), dyspepsia (4% to 6%), flatulence, dry mouth, and taste disturbances. Constipation (5.4%) has been reported in patients using the granisetron (the active ingredient contained in Sancuso) transdermal system.
Constipation appears to be dose related. In dose-finding studies, constipation occurred in up to 50% of patients treated with single doses of granisetron 300 mcg/kg. If necessary, constipation may be alleviated by the use of laxatives.
Hepatic side effects have been reported rarely. These have included elevations in serum transaminases (two times normal values). Causality is unknown. Acute pancreatitis has also been reported.
Cardiovascular side effects have included hypertension in 1% of patients. Atrial fibrillation, angina pectoris, and syncope have been reported rarely. Hypotension, sinus bradycardia, A-V block, ventricular ectopy, QT prolongation, and ECG changes have been reported as well, although causality is unknown.
Results of a review of the cardiovascular effects of the drug class 5-hydroxytryptamine 3 receptor antagonists in the literature reported that electrocardiographic (ECG) changes were so small to be considered clinically insignificant. ECG changes were most noticeable between 1 to 2 hours after a dose of granisetron and returned to baseline within 24 hours. To date, no serious cardiac side effects (including torsades de pointes) triggered by ECG interval changes have been connected with the use of 5-HT 3 receptor antagonists.
Hypersensitivity side effects have been reported rarely. These have included skin rashes, facial flushing, anaphylactoid reactions, shortness of breath, hypotension, and urticaria. One report suggests hypersensitivity reactions with 5-HT 3-antagonists may be a class effect and cross-reactive.
Other side effects including asthenia (5% to 18%) and fever (up to 8%) have been reported.
More Sancuso resources
- Sancuso Prescribing Information (FDA)
- Sancuso MedFacts Consumer Leaflet (Wolters Kluwer)
- Sancuso Advanced Consumer (Micromedex) - Includes Dosage Information
- Sancuso Consumer Overview
- granisetron MedFacts Consumer Leaflet (Wolters Kluwer)
- granisetron Oral, Intravenous Advanced Consumer (Micromedex) - Includes Dosage Information
- Granisetron Prescribing Information (FDA)
- Granisetron Hydrochloride Monograph (AHFS DI)
- Granisol Prescribing Information (FDA)
- Kytril Consumer Overview
- Kytril Prescribing Information (FDA)
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.